Treatment of Dyslipidemia in HIV

Overview

Journal Curr Atheroscler Rep

Publisher Springer

Specialty Cardiology & Vascular Diseases

Date 2015 Feb 23

PMID 25702057

Citations 8

Authors

Rajagopal V Sekhar

Affiliations

Soon will be listed here.

Abstract

Patients infected with HIV have a high risk of developing dyslipidemia. Effective therapeutic strategies can be challenging due to an increase risk of drug interactions and other comorbidities. Understanding the underlying pathophysiology and the principles of pharmacological and non-pharmacological therapeutic interventions can be of value in the appropriate management of dyslipidemia in the HIV-infected patient.

Citing Articles

Navigating Lipodystrophy: Insights from Laminopathies and Beyond.

Kruger P, Hartinger R, Djabali K Int J Mol Sci. 2024; 25(15).

PMID: 39125589 PMC: 11311807. DOI: 10.3390/ijms25158020.

Body Mass Index but not Physical Activity Level Moderates Lowered Cardiac Baroreflex Sensitivity in People Living with HIV.

Dos Santos Rangel M, Barros J, Peres D, DE Carvalho Mira P, Martinez D, Laterza M Int J Exerc Sci. 2023; 16(2):700-709.

PMID: 37650036 PMC: 10464752. DOI: 10.70252/KCZA1162.

HIV: how to manage dyslipidaemia in HIV.

Lee D Drugs Context. 2022; 11.

PMID: 35310301 PMC: 8903877. DOI: 10.7573/dic.2021-8-7.

Comparison of Tolerability and Impact on Metabolic Profiles of Antiretroviral Regimens Containing Darunavir/Ritonavir or Darunavir/Cobicistat in Romanian HIV Infected Patients.

Marin R, Tit D, Sandulescu O, Streinu-Cercel A, Bungau S Biomedicines. 2021; 9(8).

PMID: 34440191 PMC: 8392338. DOI: 10.3390/biomedicines9080987.

Dyslipidemia and cardiovascular disease in Vietnamese people with HIV on antiretroviral therapy.

Mizushima D, Dung N, Dung N, Matsumoto S, Tanuma J, Gatanaga H Glob Health Med. 2020; 2(1):39-43.

PMID: 33330773 PMC: 7731261. DOI: 10.35772/ghm.2019.01035.

References

Worm S, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F . Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis. 2009; 201(3):318-30. DOI: 10.1086/649897. View

Rose H, Hoy J, Woolley I, Tchoua U, Bukrinsky M, Dart A . HIV infection and high density lipoprotein metabolism. Atherosclerosis. 2007; 199(1):79-86. PMC: 2518204. DOI: 10.1016/j.atherosclerosis.2007.10.018. View

Lo J, You S, Wei J, Canavan B, Grinspoon S . Relationship of peak growth hormone to cardiovascular parameters, waist circumference, lipids and glucose in HIV-infected patients and healthy adults. Clin Endocrinol (Oxf). 2009; 71(6):815-22. PMC: 2889024. DOI: 10.1111/j.1365-2265.2009.03603.x. View

Grunfeld C, Pang M, Doerrler W, Shigenaga J, Jensen P, Feingold K . Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1992; 74(5):1045-52. DOI: 10.1210/jcem.74.5.1373735. View

Gagne C, Bays H, Weiss S, Mata P, Quinto K, Melino M . Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol. 2002; 90(10):1084-91. DOI: 10.1016/s0002-9149(02)02774-1. View

Palacios R, Santos J, Gonzalez M, Ruiz J, Valdivielso P, Marquez M . Efficacy and safety of atorvastatin in the treatment of hypercholesterolemia associated with antiretroviral therapy. J Acquir Immune Defic Syndr. 2002; 30(5):536-7. DOI: 10.1097/00126334-200208150-00012. View

Lee J, Chan J, Sourlas E, Raptopoulos V, Mantzoros C . Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy. J Clin Endocrinol Metab. 2006; 91(7):2605-11. DOI: 10.1210/jc.2005-1545. View

Leyes P, Martinez E, Forga M . Use of diet, nutritional supplements and exercise in HIV-infected patients receiving combination antiretroviral therapies: a systematic review. Antivir Ther. 2008; 13(2):149-59. View

Mulligan K, Grunfeld C, Tai V, Algren H, Pang M, Chernoff D . Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr. 2000; 23(1):35-43. DOI: 10.1097/00126334-200001010-00005. View

10.

Sekhar R, Jahoor F, Iyer D, Guthikonda A, Paranilam J, Elhaj F . Leptin replacement therapy does not improve the abnormal lipid kinetics of hypoleptinemic patients with HIV-associated lipodystrophy syndrome. Metabolism. 2012; 61(10):1395-403. DOI: 10.1016/j.metabol.2012.03.013. View

11.

Behrens G, Dejam A, Schmidt H, Balks H, Brabant G, Korner T . Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS. 1999; 13(10):F63-70. DOI: 10.1097/00002030-199907090-00001. View

12.

Calza L, Manfredi R, Chiodo F . Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART. AIDS. 2003; 17(6):851-9. DOI: 10.1097/00002030-200304110-00010. View

13.

Baldini F, Di Giambenedetto S, Cingolani A, Murri R, Ammassari A, De Luca A . Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: a pilot study. AIDS. 2000; 14(11):1660-2. DOI: 10.1097/00002030-200007280-00025. View

14.

Silverberg M, Leyden W, Hurley L, Go A, Quesenberry Jr C, Klein D . Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection. Ann Intern Med. 2009; 150(5):301-13. DOI: 10.7326/0003-4819-150-5-200903030-00006. View

15.

Kovacic J, Martin A, Carey D, Wand H, Mallon P, Feneley M . Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy. Antivir Ther. 2005; 10(1):135-43. View

16.

De Truchis P, Kirstetter M, Perier A, Meunier C, Zucman D, Force G . Reduction in triglyceride level with N-3 polyunsaturated fatty acids in HIV-infected patients taking potent antiretroviral therapy: a randomized prospective study. J Acquir Immune Defic Syndr. 2006; 44(3):278-85. DOI: 10.1097/QAI.0b013e31802c2f3d. View

17.

Coll B, Aragones G, Parra S, Alonso-Villaverde C, Masana L . Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients. AIDS. 2006; 20(12):1675-7. DOI: 10.1097/01.aids.0000238418.43937.3b. View

18.

Wohl D, Tien H, Busby M, Cunningham C, MacIntosh B, Napravnik S . Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia. Clin Infect Dis. 2005; 41(10):1498-504. DOI: 10.1086/497273. View

19.

Negredo E, Molto J, Puig J, Cinquegrana D, Bonjoch A, Perez-Alvarez N . Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins. AIDS. 2006; 20(17):2159-64. DOI: 10.1097/01.aids.0000247573.95880.db. View

20.

Fellay J, Boubaker K, Ledergerber B, Bernasconi E, Furrer H, Battegay M . Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet. 2001; 358(9290):1322-7. DOI: 10.1016/s0140-6736(01)06413-3. View